Andaris founder sets up contrast agent company
This article was originally published in Clinica
One of the founders of Andaris, a UK ultrasound imaging company which was sold to Quadrant Healthcare, is setting up a new company to develop novel contrast agents based on microcapsule and nanosphere technology. Richard Johnson is launching Upperton as a "virtual company", based around the R&D facilities of Nottingham University. He is looking to offer collaborative research to other companies as well as to develop Upperton's own products.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.